Company
CRTX -1.53%Crism Therapeutics Corporation
Market Cap: £7.5 Million
GBP as of Aug 2, 2026 | US$10.1 Million
$CRTX -1.53% $CRTX Healthcare BiotechnologyCompany Description
Crism Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing innovative gene-based medicines. The company's primary function is to harness the potential of a proprietary technology platform to create transformative therapies for serious diseases. Crism Therapeutics targets key areas such as genetic disorders, hemophilia, and other hematologic conditions, aiming to improve patient outcomes through precision medicine. The asset has a significant presence in the biotechnology sector, impacting areas of health technology and pharmaceuticals. As a pioneer in gene editing techniques, Crism Therapeutics plays a crucial role in advancing scientific research and development within the medical community. Its commitment to innovation makes it a critical player in the broader market, driving innovation and expanding treatment possibilities in clinically unmet needs.
Crism Therapeutics Corporation Market Capitalization Over Time
View HistoryEvolution of Crism Therapeutics Corporation market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Crism Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing innovative gene-based medicines. The company's primary function is to harness the potential of a proprietary technology platform to create transformative therapies for serious diseases. Crism Therapeutics targets key areas such as genetic disorders, hemophilia, and other hematologic conditions, aiming to improve patient outcomes through precision medicine. The asset has a significant presence in the biotechnology sector, impacting areas of health technology and pharmaceuticals. As a pioneer in gene editing techniques, Crism Therapeutics plays a crucial role in advancing scientific research and development within the medical community. Its commitment to innovation makes it a critical player in the broader market, driving innovation and expanding treatment possibilities in clinically unmet needs.
Financials
| Last Financial Reports Date | Dec. 31, 2025 |
| Revenue TTM | £231,000 |
| EBITDA | £-1,861,000 |
| Gross Profit TTM | £131,000 |
| Profit Margin | 56.71% |
| Operating Margin | -419.91% |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Crism Therapeutics Corporation main stocks and indexes inclusions.
$CRTXFTSE AIM All-Share